{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:33Z","timestamp":1790697933786,"version":"4.1.0"},"reference-count":10,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To describe morphologic changes on optical coherence tomography angiography (OCTA) in 4 eyes with exudative neovascular age-related macular degeneration (nAMD) after a switch in treatment from aflibercept to faricimab.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A total of 4 eyes from 3 patients were evaluated.\n                    <jats:bold>Results:<\/jats:bold>\n                    Three patients (4 eyes) with nAMD were included. Treatment was switched to faricimab due to inadequate control of exudation or limited treatment interval extension with other antivascular endothelial growth factor (anti-VEGF) therapies. All eyes showed morphologic changes in macular neovascularization (MNV) on OCTA after the switch from aflibercept to faricimab. The MNV trunk persisted in all eyes, with regression of the lacy vasculature after treatment. Despite residual MNV, exudation was well controlled in all eyes at 9- to 11-week treatment intervals. Notably, morphologic changes were seen on OCTA even when structural findings remained largely unchanged.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Long-term faricimab therapy is associated with distinct morphologic changes in MNV seen on OCTA that were not observed with other anti-VEGF therapies, highlighting the added value of OCTA for assessing treatment response.\n                  <\/jats:p>","DOI":"10.1177\/24741264261427833","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:32:02Z","timestamp":1773588722000},"page":"764-769","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Morphologic Changes of Macular Choroidal Neovascularization on OCT Angiography Following Faricimab Therapy in Patients With AMD"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2136-4650","authenticated-orcid":false,"given":"Asad","family":"Loya","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Chen","sequence":"additional","affiliation":[{"name":"Methodist Hospital Department of Ophthalmology, Weill Cornell Medicine, Houston, TX, USA"},{"name":"Retina and Vitreous of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prethy","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA"},{"name":"Methodist Hospital Department of Ophthalmology, Weill Cornell Medicine, Houston, TX, USA"},{"name":"Retina and Vitreous of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-6686","authenticated-orcid":false,"given":"Emmanuel Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA"},{"name":"Methodist Hospital Department of Ophthalmology, Weill Cornell Medicine, Houston, TX, USA"},{"name":"Retina and Vitreous of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30489-7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.OPHTHA.2019.11.004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJO.2015.04.012"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20151008-02"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220516-01"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001576"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/BJOPHTHALMOL-2018-313685"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01377-x"},{"issue":"8","key":"e_1_3_2_10_2","first-page":"349","article-title":"Simultaneous Ang-2\/VEGF-A inhibition prevents subretinal fibrosis progression in preclinical mouse models of choroidal neovascularization (CNV)","volume":"62","author":"Linder M","year":"2021","unstructured":"Linder M, Foxton R, Uhles S, et al. Simultaneous Ang-2\/VEGF-A inhibition prevents subretinal fibrosis progression in preclinical mouse models of choroidal neovascularization (CNV). Invest Ophthalmol Vis Sci. 2021;62(8):349-349.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/FNCEL.2023.1192464\/BIBTEX"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261427833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261427833","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261427833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:26:09Z","timestamp":1790695569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261427833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/24741264261427833"],"URL":"https:\/\/doi.org\/10.1177\/24741264261427833","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]}}}